BMJ Open (Sep 2022)

Hypofractionated versus conventional intensity-modulated radiation irradiation (HARVEST-adjuvant): study protocol for a randomised non-inferior multicentre phase III trial

  • Min Li,
  • Fei Xu,
  • Jian Li,
  • Min Chen,
  • Mei Chen,
  • Cheng Xu,
  • Yuan Yao,
  • Rong Cai,
  • Qing Lin,
  • Xiao Lin,
  • Yimin Han,
  • Feifei Xu,
  • Jinrong Xie,
  • Yutian Zhao,
  • Gang Cai,
  • Qiwei Zhu,
  • Shubei Wang,
  • Xiaolu Tang,
  • Chuying Chen,
  • Siyue Zheng,
  • Xiaofang Qian,
  • Chunhong Shen,
  • Haoping Xu,
  • Dan Ou,
  • Kun Wei Shen,
  • Wei-Xiang Qi,
  • Lu Cao,
  • Xiaobo Huang,
  • Jiayi Chen

DOI
https://doi.org/10.1136/bmjopen-2022-062034
Journal volume & issue
Vol. 12, no. 9

Abstract

Read online

Introduction Short course regimen has become the major trend in the field of adjuvant radiotherapy for patients with breast cancer. Hypofractionated radiotherapy (HF-RT) regimen of 40–42.5 Gy in 15–16 fractions has been established as a preferred option for whole breast irradiation. However, few evidences of hypofractionated regional nodal irradiation (RNI), especially involving internal mammary nodes (IMNs), could be available during the era of intensity-modulated radiation therapy (IMRT). Against this background, we design this trial to explore the hypothesis that HF-RT regimen involving RNI (including infraclavicular, supraclavicular nodes and IMNs) will be non-inferior to a standard schedule by using IMRT technique.Methods and analysis This is an open-label randomised, non-inferior, multicentre phase III trial. Patients with breast cancer with an indication for RNI after breast conserving surgery or mastectomy are randomised at a ratio of 1:1 into the following two groups: hypofractionated regimen of 2.67 Gy for 16 fractions or conventional regimen of 2 Gy for 25 fractions. The dose was prescribed to ipsilateral chest wall or whole breast and RNI (including infraclavicular, supraclavicular nodes and IMNs, lower axilla if indicated). The trial plans to enrol a total of 801 patients and all patients will be treated using IMRT technique. The primary endpoint is 5-year locoregional recurrence. The secondary endpoints include 5-year distant metastasis free survival, invasive recurrence-free survival, overall survival, accumulative acute radiation-induced toxicity and accumulative late radiation-induced toxicity, cosmetic outcomes and quality of life.Ethics and dissemination The study has been approved by the Ethical Committee of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine (version 2018-95-3) and approvals from ethical committee of each participating centre have also been obtained. Research findings will be submitted for publication in peer-reviewed journals.Trial registration number NCT03829553.